{"id":"W2123235255","doi":"10.1200/jco.2010.33.6594","title":"Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Medicine; Bortezomib; Follicular lymphoma; Internal medicine; Rituximab; Vincristine; Surgery; Prednisone; Gastroenterology; Cyclophosphamide; Lymphoma; Chemotherapy; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002544022,0.0008875736,0.00188799,0.0003278155,0.0004280473,0.0008064144,0.0009484568,0.0009321648,0.002033114],"category_scores_gemma":[0.001380939,0.0004422126,0.0009934016,0.0005674617,0.001010436,0.0004607959,0.0002629195,0.002352909,0.0003615568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002476793,"about_ca_system_score_gemma":0.003126978,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01009856,"about_ca_topic_score_gemma":0.02182758,"domain_scores_codex":[0.9991961,0.0003977156,0.00004367279,0.0001187675,0.0001472505,0.00009643379],"domain_scores_gemma":[0.9988907,0.0001694203,0.0003001352,0.00008463821,0.0001128793,0.0004421819],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7697583,0.02998861,0.0204762,0.001216775,0.003611655,0.0003392169,0.0003245581,0.002325659,0.02958236,0.0001427814,0.004031003,0.138203],"study_design_scores_gemma":[0.6578465,0.2814124,0.04879039,0.00009894844,0.001133846,0.000582005,0.00005114291,0.001225981,0.003125836,0.00009286131,0.005602569,0.00003762958],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893832,0.006513247,0.0003324279,0.0003450027,0.00005898103,0.001474491,0.0006906249,0.00005766959,0.001144366],"genre_scores_gemma":[0.9901993,0.004141158,0.001274595,0.0004971957,0.0001550615,0.0009628489,0.001672601,0.00001736315,0.001079813],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01009856,"threshold_uncertainty_score":0.02007955,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2167261987483562,"score_gpt":0.5308915157766564,"score_spread":0.3141653170283001,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}